This study is being done to evaluate the frequency and clinical phenotype of BAP1 hereditary predisposition syndrome.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04792463.
Locations matching your search criteria
United States
Ohio
Columbus
Ohio State University Comprehensive Cancer CenterStatus: Active
Contact: Mohamed H. Abdel-Rahman
Phone: 614-292-1396
PRIMARY OBJECTIVE:
I. Identify the frequency and clinical spectrum of patients with germline BAP1 mutation.
II. Study the potential contribution of germline gene rearrangements and epigenetic inactivation (epimutations) to inactivation of BAP1.
OUTLINE: This is an observational study.
Patients undergo blood sample collection on study. Patients' medical records are also reviewed. Patients with a hereditary positive result are offered genetic counseling.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationOhio State University Comprehensive Cancer Center
Principal InvestigatorMohamed H. Abdel-Rahman